Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stevens, L. A.
Right arrow Articles by Levin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevens, L. A.
Right arrow Articles by Levin, A.
Related Collections
Right arrowRelated Article
J Am Soc Nephrol 15:770-779, 2004
© 2004 American Society of Nephrology

CLINICAL SCIENCE

Calcium, Phosphate, and Parathyroid Hormone Levels in Combination and as a Function of Dialysis Duration Predict Mortality: Evidence for the Complexity of the Association between Mineral Metabolism and Outcomes

Lesley A. Stevens*,{dagger}, Ognjenka Djurdjev{ddagger}, Savannah Cardew§, E. C. Cameron{dagger} and Adeera Levin{dagger}

*Division of Nephrology, New England Medical Centre, Boston, Massachusetts; {dagger}Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; {ddagger}Centre for Health Evaluation & Outcome Sciences (CHEOS), University of British Columbia, Vancouver, British Columbia, Canada; §University of British Columbia Medical School, Vancouver, British Columbia, Canada.

Correspondence to Dr. Adeera Levin, Division of Nephrology, Department of Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada. Phone: 604-681-7191; Fax: 604-806-8120; E-mail: alevin{at}providencehealth.bc.ca

ABSTRACT. Current literature suggests associations between abnormal mineral metabolism (MM) to cardiovascular disease in dialysis populations, with conflicting results. MM physiology is complex; therefore, it was hypothesized that constellations of MM parameters, reflecting this complexity, would be predictive of mortality and that this effect would be modified by dialysis duration (DD). Prevalent dialysis patients in British Columbia, Canada, who had measurements of calcium (Ca), phosphate (Pi), and parathyroid hormone (iPTH) between January and March 2000 were followed prospectively until December 2002. Statistical analysis included Cox proportional hazard models with Ca, Pi, and iPTH alone and in combination as explanatory variables; analyses were stratified by DD. The 515 patients included in this analysis represent British Columbia and Canadian dialysis populations: 69% were on hemodialysis, mean age was 60 ± 17 yr, 40% were female, and 34% had diabetes. Mean Ca and Pi values were 2.32 ± 0.22 mmol/L and 1.68 ± 0.59 mmol/L, respectively, and median iPTH was 15.8 pmol/L (25th to 75th percentile: 6.9 to 37.3 pmol/L). Serum Pi, after adjusting for demographic, dialysis type and adequacy, hemoglobin, and albumin, independently predicted mortality (risk ratio [RR], 1.56 per 1 mmol/L; 95% confidence interval [CI], 1.15 to 2.12; P = 0.004). When combinations of parameters were modeled (overall P = 0.003), the combinations of high serum Pi and Ca with high iPTH (RR, 3.71; 95% CI, 1.53 to 9.03; P = 0.004) and low iPTH (RR, 4.30; 95% CI, 2.01 to 9.22; P < 0.001) had highest risks for mortality as compared with the combination of high iPTH with normal serum Ca and Pi that had the lowest mortality and was used as index category. These effects varied across different strata of DD. This analysis demonstrates the importance of examining combinations of MM parameters as opposed to single variables alone and the effect of DD. In so doing, the complex interaction of time and MM can begin to be understand. Further exploration is required.


Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2004 15: A24-A26. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease
Nephrol. Dial. Transplant., November 11, 2008; (2008) gfn613v1.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. D. Danese, V. Belozeroff, K. Smirnakis, and K. J. Rothman
Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1423 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Mathew, R. J. Lund, L. R. Chaudhary, T. Geurs, and K. A. Hruska
Vitamin D Receptor Activators Can Protect against Vascular Calcification
J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1509 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
V. M. Brandenburg and J. Floege
Adynamic bone disease--bone and beyond
NDT Plus, June 1, 2008; 1(3): 135 - 147.
[Full Text] [PDF]

Home page
 CJASNHome page
P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy
Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. J Bolland, P A. Barber, R. N Doughty, B. Mason, A. Horne, R. Ames, G. D Gamble, A. Grey, and I. R Reid
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial
BMJ, February 2, 2008; 336(7638): 262 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
U. Kunzendorf, B. K. Kramer, W. Arns, J. Braun, J. Grossmann, F. Pietruck, H. Schmidt-Gayk, A. Schwarz, E. Ziegler, H. Sperschneider, et al.
Bone disease after renal transplantation
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 450 - 458.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
L. Gnudi
Serum intact parathyroid hormone in diabetic patients on haemodialysis: what is the treatment goal?
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 24 - 26.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. J Lamb, A. Hodsman, D. van Schalkwyk, D. Ansell, and G. Warwick
Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (Chapter 9)
Nephrol. Dial. Transplant., August 1, 2007; 22(suppl_7): vii105 - vii118.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
R. N. Foley
Phosphorus Comes of Age as a Cardiovascular Risk Factor
Arch Intern Med, May 14, 2007; 167(9): 873 - 874.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Rashid, J. Bernheim, J. Green, and S. Benchetrit
Cardiovascular Events and Parathyroid Hormone--Suggestion of a Further Link
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1023 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Tomiyama, A. Higa, M. A. Dalboni, M. Cendoroglo, S. A. Draibe, L. Cuppari, A. B. Carvalho, E. M. Neto, and M. E. F. Canziani
The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients
Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2464 - 2471.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Albalate, C. de la Piedra, C. Fernandez, M. Lefort, H. Santana, P. Hernando, J. Hernandez, and C. Caramelo
Association between phosphate removal and markers of bone turnover in haemodialysis patients
Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1626 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. P. Schmitt, T. Odenwald, and E. Ritz
Calcium, Calcium Regulatory Hormones, and Calcimimetics: Impact on Cardiovascular Mortality
J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S78 - S80.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
F. K. Port, R. L. Pisoni, J. Bommer, F. Locatelli, M. Jadoul, G. Eknoyan, K. Kurokawa, B. J. Canaud, M. P. Finley, and E. W. Young
Improving Outcomes for Dialysis Patients in the International Dialysis Outcomes and Practice Patterns Study
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 246 - 255.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
G. Block
Calcium, Calcimimetics and Clinical Outcomes
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 170 - 171.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
I. Lopez, E. Aguilera-Tejero, F. J. Mendoza, Y. Almaden, J. Perez, D. Martin, and M. Rodriguez
Calcimimetic R-568 Decreases Extraosseous Calcifications in Uremic Rats Treated with Calcitriol
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 795 - 804.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton
CHAPTER 3: Mineral Metabolism
J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S11 - S15.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
V. Lorenzo, A. Martin-Malo, R. Perez-Garcia, J. V. Torregrosa, N. Vega, A. L. M. de Francisco, and A. Cases
Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study
Nephrol. Dial. Transplant., February 1, 2006; 21(2): 459 - 465.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Morena, N. Terrier, I. Jaussent, H. Leray-Moragues, L. Chalabi, J.-P. Rivory, F. Maurice, C. Delcourt, J.-P. Cristol, B. Canaud, et al.
Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 262 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Kimata, T. Akiba, R. L. Pisoni, J. M. Albert, S. Satayathum, J. M. Cruz, T. Akizawa, V. E. Andreucci, E. W. Young, and F. K. Port
Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Nephrol. Dial. Transplant., May 1, 2005; 20(5): 927 - 935.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
L. Nanovic
Electrolytes and Fluid Management in Hemodialysis and Peritoneal Dialysis
Nutr Clin Pract, April 1, 2005; 20(2): 192 - 201.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Ketteler, V. Brandenburg, W. Jahnen-Dechent, R. Westenfeld, and J. Floege
Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse
Nephrol. Dial. Transplant., April 1, 2005; 20(4): 673 - 677.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Teng, M. Wolf, M. N. Ofsthun, J. M. Lazarus, M. A. Hernan, C. A. Camargo Jr, and R. Thadhani
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1115 - 1125.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. M. Chertow and S. M. Moe
Calcification or Classification?
J. Am. Soc. Nephrol., February 1, 2005; 16(2): 293 - 295.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. Kestenbaum, J. N. Sampson, K. D. Rudser, D. J. Patterson, S. L. Seliger, B. Young, D. J. Sherrard, and D. L. Andress
Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease
J. Am. Soc. Nephrol., February 1, 2005; 16(2): 520 - 528.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673